In:
Pacing and Clinical Electrophysiology, Wiley, Vol. 28, No. s1 ( 2005-01)
Abstract:
Nifekalant (NF), a pure K + channel blocker developed in Japan, has been reported to be effective in the treatment of life‐threatening ventricular arrhythmias. We studied its efficacy in 18 men and 4 women with out‐of‐hospital ventricular fibrillation (VF) admitted to our emergency department between August 2001 and March 2004. The number of DC shocks delivered for out‐of‐hospital VF, serum Na + and K + , arterial blood pH, and base excess were compared in 8 patients treated with NF, 0.3 mg/kg i.v. followed by a continuous intravenous (group N) versus 14 patients treated with lidocaine, 2 mg/kg, i.v. (group C). The two groups were similar with respect to their baseline characteristics. Sinus rhythm returned in 5 of 8 patients in group N versus 2 of 14 patients in group C (P 〈 0.05). These seven patients were admitted to the intensive care unit, though all died within 1 month. The results of this study suggest that NF may be effective in defibrillation of out‐of‐hospital VF, though controlled studies are needed to confirm our observations.
Type of Medium:
Online Resource
ISSN:
0147-8389
,
1540-8159
DOI:
10.1111/pace.2005.28.issue-s1
DOI:
10.1111/j.1540-8159.2005.00043.x
Language:
English
Publisher:
Wiley
Publication Date:
2005
detail.hit.zdb_id:
2037547-5
Permalink